Advertisement
Screener

Omada Health, Inc. (OMDA) Graph

OMDA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $87.83M; Cost of revenue $24.05M; Research and development $14.63M; Operating expenses $60.24M.
  • 2026-03-31: Revenue $78.05M; Cost of revenue $29.36M; Research and development $12.70M; Operating expenses $53.47M.
  • 2025-12-31: Revenue $75.85M*; Cost of revenue $22.18M*; Research and development $11.55M*; Operating expenses $50.38M*.
  • 2025-09-30: Revenue $68.03M; Cost of revenue $22.96M; Research and development $10.30M; Operating expenses $47.58M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OMDA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Service$80.69MHardware$7.14MRevenue$87.84MCost of revenue$24.05MGross profit$63.79MOperating expenses$60.24MOperating income$3.55MResearch & development$14.62MPre-tax income$5.29MIncome tax$0.00Net income$5.29M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

OMDA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$87.84MRevenue$87.84MCost of revenue$24.05MGross profit$63.79MOperating expenses$60.24MOperating income$3.55MResearch & development$14.62MPre-tax income$5.29MIncome tax$0.00Net income$5.29M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$87.83M$24.05M$14.63M$60.24M$0.00$5.29M
2026-03-31$78.05M$29.36M$12.70M$53.47M$0.00-$2.97M
2025-12-31$75.85M*$22.18M*$11.55M*$50.38M*$0.00*$5.16M*
2025-09-30$68.03M$22.96M$10.30M$47.58M$0.00-$3.18M
2025-06-30$61.37M$21.07M$10.02M$44.65M$0.00-$5.31M
2025-03-31$54.96M$23.06M$8.81M$40.30M$0.00-$9.45M
2024-09-30$45.52M$16.95M$8.85M$37.09M$0.00-$9.23M
2024-06-30$41.21M$16.38M$8.99M$34.87M$0.00-$10.69M
2024-03-31(m)(m)(m)(m)(m)-$18.97M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30$165.88M$53.40M$27.32M$113.71M$0.00$2.32M
2025-06-30$116.33M$44.13M$18.83M$84.95M$0.00-$14.76M
2024-06-30$76.31M$34.13M$17.88M$70.21M$0.00-$29.66M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$184.36M$67.09M$29.13M$132.53M$0.00-$17.94M
2024-09-30$121.82M$51.08M$26.73M$107.30M$0.00-$38.89M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$260.21M$89.27M$40.68M$182.91M$0.00-$12.78M
2024-12-31$169.80M$66.92M$35.92M$146.53M$0.00-$47.14M
2023-12-31$122.78M$52.81M$33.74M$135.97M$0.00-$67.51M

Similar stocks

Stock NameCountryMarket CapPE Ratio
InnovAge Holding Corp. (INNV)United States$1.206B-635.60
U S PHYSICAL THERAPY INC /NV (USPH)United States$1.251B32.48
Pennant Group, Inc. (PNTG)United States$1.386B39.84
Strata Critical Medical, Inc. (SRTA)United States$0.467B11.33
DocGo Inc. (DCGO)United States$0.034B-0.25
VSEE HEALTH, INC. (VSEE)United States$0.003B
Agape ATP Corp (ATPC)$0.002B
Privia Health Group, Inc. (PRVA)United States$2.477B115.52
GeneDx Holdings Corp. (WGS)United States$2.638B-19.23
LifeStance Health Group, Inc. (LFST)United States$4.510B80.86